Exploring Brain Metabolism and Cognitive Impairment in Childhood-Onset Systemic Lupus Using Fluorodeoxyglucose Positron Emission Tomography [0.03%]
使用氟脱氧葡萄糖正电子发射断层扫描探讨儿童期发病的系统性红斑狼疮患者的脑代谢及认知障碍问题
Flávia Patrícia Sena Teixeira Santos,Gilda Aparecida Ferreira,Alexei Manso Machado et al.
Flávia Patrícia Sena Teixeira Santos et al.
Objectives: As biochemical and functional abnormalities often precede structural changes in disease, fluorine-18 fluorodeoxyglucose positron emission tomography may allow early detection of cerebral involvement in neurops...
Predictors of the late recurrences of immunoglobulin A vasculitis due to clinical and laboratory features in children [0.03%]
儿童免疫球蛋白A血管炎晚期复发的预测因素——临床及实验室指标分析
Deniz Gezgin Yildirim,Emine Nur Sunar Yayla,Cisem Yildiz et al.
Deniz Gezgin Yildirim et al.
Objectives: This study aims to evaluate the frequency and predictors of immunoglobulin A vasculitis (IgAV) late relapses based on clinical and laboratory features in children. ...
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study [0.03%]
在SELECT-EARLY研究中，托法替布单药治疗与甲氨蝶呤单药治疗在日本既往未接受甲氨蝶呤治疗的类风湿关节炎患者中的长达5年疗效和安全性分析
Tsutomu Takeuchi,Ronald Vollenhoven,Yukitaka Ueki et al.
Tsutomu Takeuchi et al.
Objective: To evaluate the long-term (5-year) efficacy and safety of upadacitinib monotherapy compared with methotrexate (MTX) monotherapy in Japanese patients with rheumatoid arthritis included in the Phase 3 SELECT-EARL...
Umbilical cord-derived mesenchymal stem cell therapy for knee osteoarthritis and cartilage repair: Current evidence and clinical applications [0.03%]
脐带间充质干细胞治疗膝骨关节炎和软骨修复：现有证据及临床应用
Jin Kyu Lee,Norimasa Nakamura
Jin Kyu Lee
Osteoarthritis is fundamentally a whole-joint disease, and a critical pathological feature is the limited capacity of articular cartilage for self-regeneration, leading to accelerated joint degeneration once breakdown begins. Current therap...
Satoshi Kubo
Satoshi Kubo
The expansion of targeted therapies and the widespread adoption of treat-to-target (T2T) strategies have substantially improved outcomes for rheumatoid arthritis (RA). However, patient populations remain highly heterogeneous in routine clin...
Efficacy and safety of canakinumab in patients with Adult-Onset Still's Disease: Results from an open-label Phase III study in Japan [0.03%]
卡那单抗治疗日本成人Still病患者疗效和安全性III期开放标签研究结果
Tatsuya Atsumi,Yohei Kirino,Mitsumasa Kishimoto et al.
Tatsuya Atsumi et al.
Objectives: To evaluate the efficacy and safety of canakinumab 4 mg/kg every 4 weeks administered subcutaneously in Japanese AOSD patients. Methods: ...
A proposal for the implementation of telemedicine in Japan for rheumatoid arthritis, juvenile idiopathic arthritis, and systemic lupus erythematosus: review article [0.03%]
日本类风湿关节炎、幼年特发性关节炎和系统性红斑狼疮实施远程医疗的提案：综述文章
Shin-Ya Kawashiri,Atsushi Kawakami,Takako Miyamae
Shin-Ya Kawashiri
Telemedicine is a promising solution for addressing regional disparities and improving access to specialized care for patients with rheumatic diseases in Japan. This review provides a comprehensive overview of the current challenges, propos...
Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Baricitinib: A Prospective Observational Study in Japan [0.03%]
巴瑞克替尼治疗类风湿关节炎患者的结局研究：一项日本前瞻性观察性研究
Yuko Kaneko,Naoto Tsujimoto,Izumi Sato et al.
Yuko Kaneko et al.
Objectives: This real-world study evaluated the effectiveness of baricitinib on activities of daily living (ADL) and health-related quality of life (HRQoL) in patients with rheumatoid arthritis (RA) in Japan and explored ...
Integrated Safety Analysis of Filgotinib in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Over a Treatment Duration of up to 5 Years [0.03%]
用于治疗中至重度活动性类风湿关节炎的Filgotinib在日本患者长达五年给药间隔内的综合安全性分析
Yoshiya Tanaka,Akira Kondo,Hisaaki Isaji et al.
Yoshiya Tanaka et al.
Objective: To evaluate long-term safety of filgotinib as treatment of moderately to severely active rheumatoid arthritis (RA) for up to 5 years in Japanese patients. ...
Effectiveness and Safety of Sarilumab in Polymyalgia Rheumatica: a retrospective study of the FIRST Registry [0.03%]
司妥昔单抗治疗多肌炎的疗效及安全性：FIRST登记处的一项回顾性研究
Naoaki Ohkubo,Yusuke Miyazaki,Satoshi Kubo et al.
Naoaki Ohkubo et al.
Objective: To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis (RA). ...